A genetic mutation that promotes cancer development blocks the normal sorting of a protein called “Argonaute 2.”

A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study. TNBC is the only type of breast cancer for which there are no currently approved targeted therapies.

Jennifer Pietenpol, Ph.D., director of the Vanderbilt-Ingram Cancer Center, B.F. Byrd Jr. Professor of Molecular Oncology and Professor of Biochemistry, Cancer Biology and Otolaryngology, has been named Executive Vice President for Research at Vanderbilt University Medical Center (VUMC). Her appointment is effective May 1.

Signaling by a receptor that is overexpressed in aggressive forms of breast cancer has been linked to glutamine metabolism, suggesting new anti-cancer therapeutic targets.

The symptoms of head and neck cancer can be subtle. To help catch the disease in its earliest stages, the Vanderbilt Department of Otolaryngology-Head and Neck Surgery and Vanderbilt-Ingram Cancer Center will offer free head and neck cancer screenings Friday, April 15.

The symptoms of head and neck cancer can be subtle, so to help catch the disease in its earliest stages the Vanderbilt Department of Otolaryngology-Head and Neck Surgery and Vanderbilt-Ingram Cancer Center will offer free head and neck screenings Friday, April 15, from 9 a.m. to 3 p.m.

A cancer patient’s gratitude toward his Vanderbilt-Ingram Cancer Center (VICC) physician led to a star-studded concert to benefit the Cancer Center.